WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ...
Selecta Biosciences, Inc. SELB announced that the FDA has placed a clinical hold on its phase I/II study, which is evaluating its pipeline candidate SEL-302 for the treatment of patients with ...
An analyst has reiterated that Selecta Biosciences' portfolio is “promising” despite the biotech offloading a quarter of its workforce along with non-partnered gene therapy programs. The company, ...
Selecta Biosciences Inc SELB provided an update on its ongoing strategic initiative to maximize stockholder value related to its economic interests in SEL-212, which is being developed for the ...
Selecta Biosciences presented more new data from an ongoing phase 2 trial of its enzyme treatment for gout, which the company said outperformed standard treatment and has convinced it to soldier on to ...
Selecta Biosciences and Ginkgo Bioworks are extending their alliance to cover gene therapy delivery. Just months after disclosing a rare disease pact, the partners have unwrapped a second deal focused ...
(RTTNews) - Selecta Biosciences Inc. (SELB) expects topline data from the Phase 3 DISSOLVE clinical program investigating SEL-212 in chronic refractory gout in the first-quarter of 2023. The company ...
WATERTOWN, Mass. and STOCKHOLM, Sweden, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI), today announced topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results